Clearside Biomedical Shares Surge Amid Bankruptcy Proceedings

Clearside Biomedical US1850631045

In a surprising market move, shares of Clearside Biomedical (CLSD) are experiencing a powerful rally, advancing by nearly 29 percent. This significant upward momentum starkly contrasts with the company's operational reality, as it has been operating under a voluntary Chapter 11 bankruptcy process since November 2025. The equity is no longer listed on the Nasdaq and now trades exclusively over-the-counter (OTC).

The focal point of the current situation is Clearside Biomedical's portfolio of ophthalmological assets, which are being offered for sale. The company initiated the Chapter 11 proceedings to facilitate an orderly sale of its business operations, aiming to maximize value for creditors. The US Bankruptcy Court granted approval for the sale processes in December 2025.

Central to the sale is the company's proprietary suprachoroidal (SCS®) delivery platform, a technology designed for targeted drug administration in the eye. This platform underpins several key programs, including the flagship candidate CLS-AX for wet age-related macular degeneration (wet AMD), which is prepared to enter Phase 3 clinical trials. The technology is also utilized in the approved product ARCATUS® in Australia and Singapore, and the company maintains a collaboration with BioCryst Pharmaceuticals.

• Bankruptcy Status: A voluntary Chapter 11 petition was filed in November 2025.
• Exchange Status: The stock was delisted from the Nasdaq in December 2025.
• Sale Process: Court-approved bidding procedures for an asset sale are currently underway.

Divergence Between Analyst Views and Trading Reality

A notable discrepancy exists between the stock's market price and historical analyst ratings. The equity is currently valued at approximately $1.17. However, five analysts maintain a "Buy" rating on CLSD, with an average price target of $4.80. It is crucial to note that these assessments predate the bankruptcy filing and do not reflect the new realities of OTC trading. Recent technical indicators had previously signaled a bearish sentiment for the stock.

Today's substantial price increase demonstrates that investor interest in the company's core technology and pipeline remains, even within the context of bankruptcy proceedings. The final outcome of the asset sale will ultimately determine the realized value of these medical assets and define any potential recovery for the company's shareholders.

@ boerse-global.de | US1850631045 CLEARSIDE